Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 10/2022

11.10.2022 | Lungenkarzinome | Zertifizierte Fortbildung

Lungenkrebs

Diagnostik und Therapie des kleinzelligen Lungenkarzinoms

verfasst von: Prof. Dr. med. Niels Reinmuth, PD Dr. med. Thomas Duell, Martina Merk

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Auszug

Das kleinzellige Lungenkarzinom ist durch einen aggressiven Verlauf mit früher Metastasierung gekennzeichnet. Auch wenn die Prognose weiterhin ungünstig ist, hat die Addition von Immuncheckpointinhibitoren zur Chemotherapie dazu beigetragen, das Gesamtüberleben für Betroffene im Stadium IV zu verbessern. Über die Behandlung in frühen und späten Stadien sowie die Diagnostik lesen Sie in dieser Übersicht zu den aktuellen Standards.
Literatur
1.
Zurück zum Zitat Kraywinkel K, Barnes B. Epidemiologie des kleinzelligen Lungenkarzinoms in Deutschland. Onkologe. 2017;23(5):334-39 Kraywinkel K, Barnes B. Epidemiologie des kleinzelligen Lungenkarzinoms in Deutschland. Onkologe. 2017;23(5):334-39
2.
Zurück zum Zitat Emrich K, Kraywinkel K. Epidemiologie des kleinzelligen Lungenkarzinoms in Deutschland. Onkologe. 2021;27(9):858-60 Emrich K, Kraywinkel K. Epidemiologie des kleinzelligen Lungenkarzinoms in Deutschland. Onkologe. 2021;27(9):858-60
3.
Zurück zum Zitat Nicholson AG et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(3):300-11 Nicholson AG et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(3):300-11
4.
Zurück zum Zitat Goeckenjan G et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie. 2010;65(1):39-59 Goeckenjan G et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie. 2010;65(1):39-59
6.
Zurück zum Zitat Dingemans AC et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(7):839-53 Dingemans AC et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(7):839-53
7.
Zurück zum Zitat Reinmuth N, Hoffmann H. [Small Cell Lung Cancer]. Pneumologie. Pneumologie. 2021;75(4):304-18 Reinmuth N, Hoffmann H. [Small Cell Lung Cancer]. Pneumologie. Pneumologie. 2021;75(4):304-18
8.
Zurück zum Zitat Schreiber D et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010;116(5):1350-7 Schreiber D et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010;116(5):1350-7
9.
Zurück zum Zitat Auperin A et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476-84 Auperin A et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476-84
10.
Zurück zum Zitat Pezzi TA et al. Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation. JAMA Netw Open. 2020;3(4):e201929 Pezzi TA et al. Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation. JAMA Netw Open. 2020;3(4):e201929
11.
Zurück zum Zitat Simo M et al. Brain damage following prophylactic cranial irradiation in lung cancer survivors. Brain Imaging Behav. 2016;10(1):283-95 Simo M et al. Brain damage following prophylactic cranial irradiation in lung cancer survivors. Brain Imaging Behav. 2016;10(1):283-95
12.
Zurück zum Zitat Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer. 1990;61(4):584-9 Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer. 1990;61(4):584-9
13.
Zurück zum Zitat Horn L et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220-9 Horn L et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220-9
14.
Zurück zum Zitat Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-39 Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-39
15.
Zurück zum Zitat O'Brien ME et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441-7 O'Brien ME et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441-7
16.
Zurück zum Zitat von Pawel J et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012-9 von Pawel J et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012-9
17.
Zurück zum Zitat Takahashi T et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663-71 Takahashi T et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663-71
18.
Zurück zum Zitat Slotman BJ et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2014;385(9962):36-42 Slotman BJ et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2014;385(9962):36-42
Metadaten
Titel
Lungenkrebs
Diagnostik und Therapie des kleinzelligen Lungenkarzinoms
verfasst von
Prof. Dr. med. Niels Reinmuth
PD Dr. med. Thomas Duell
Martina Merk
Publikationsdatum
11.10.2022
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 10/2022
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-022-9707-x

Weitere Artikel der Ausgabe 10/2022

InFo Hämatologie + Onkologie 10/2022 Zur Ausgabe